Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex

Journal of Proteome Research

Volumn 8, Issue 7, 2009, Pages 3284-3297

  Ma, Dan ^a   Chan, Man K ^a   Lockstone, Helen E ^a   Pietsch, Sandra R ^a   Jones, Declan N C ^b   Cilia, Jackie ^b   Hill, Mark D ^b   Robbins, Melanie J ^b   Benzel, Isabel M ^b   Umrania, Yagnesh ^a   Guest, Paul C ^a   Levin, Yishai ^a   Maycox, Peter R ^b   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Development; Haloperidol; Olanzapine; Proteomics; Rat; Synaptic

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; GLUCONEOGENESIS; GLYCOLYSIS; HUNTINGTON CHOREA; LIQUID CHROMATOGRAPHY; MALE; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; CHROMATOGRAPHY, LIQUID; DETERGENTS; FRONTAL LOBE; HALOPERIDOL; MALE; MASS SPECTROMETRY; NERVOUS SYSTEM; PROTEOMICS; RATS; RATS, WISTAR; SYNAPTIC TRANSMISSION;

RATTUS;

EID: 67650354396     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800983p     Document Type: Article

References (74)

1. Laruelle, M.; Frankle, W. G.; Narendran, R.; Kegeles, L. S.; Abi-Dargham, A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 2005, 27 (Suppl. A), S16-24.
2. Smith, R. C.; Infante, M.; Singh, A.; Khandat, A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int. J. Neuropsychopharmacol. 2001, 4 (3), 239-50.
3. Lublin, H.; Eberhard, J.; Levander, S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. 2005, 20 (4), 183-98.
4. Newcomer, J. W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 2007, 68 (Suppl. 4), 8-13.
5. Leucht, C.; Kitzmantel, M.; Chua, L.; Kane, J.; Leucht, S. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst. Rev. 2008, (1), CD004278.
6. Gianfrancesco, F. D.; Grogg, A. L.; Mahmoud, R. A.; Wang, R. H.; Nasrallah, H. A. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry 2002, 63 (10), 920-30.
7. Green, A. I.; Lieberman, J. A.; Hamer, R. M.; Glick, I. D.; Gur, R. E.; Kahn, R. S.; McEvoy, J. P.; Perkins, D. O.; Rothschild, A. J.; Sharma, T.; Tohen, M. F.; Woolson, S.; Zipursky, R. B. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr. Res. 2006, 86 (1-3), 234-43.
8. Wong, A. H.; Van Tol, H. H. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev. 2003, 27 (3), 269-306.
9. Horacek, J.; Bubenikova-Valesova, V.; Kopecek, M.; Palenicek, T.; Dockery, C.; Mohr, P.; Hoschl, C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20 (5), 389-409.
10. Di Pietro, N. C.; Seamans, J. K. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 2007, 40 (Suppl. 1), S27-33.
11. Huang, X. F.; Han, M.; Huang, X.; Zavitsanou, K.; Deng, C. Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav. Brain Res. 2006, 171 (2), 355-62.
12. Green, W.; Patil, P.; Marsden, C. A.; Bennett, G. W.; Wigmore, P. M. Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex. Brain Res. 2006, 1070 (1), 242-5.
13. Kurosawa, S.; Hashimoto, E.; Ukai, W.; Toki, S.; Saito, S.; Saito, T. Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. J. Neural Transm. 2007, 114 (9), 1121-8.
14. Pillai, A.; Mahadik, S. P. Differential effects of haloperidol and olanzapine on the expression of erythropoietin and its receptor in rat hippocampus and striatum. J. Neurochem. 2006, 98 (5), 1411-22.
15. Halim, N. D.; Weickert, C. S.; McClintock, B. W.; Weinberger, D. R.; Lipska, B. K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004, 29 (6), 1063-9.
16. Dwyer, D. S.; Lu, X. H.; Bradley, R. J. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res. 2003, 971 (1), 31-9.
17. Thomas, E. A. Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol. Neurobiol. 2006, 34 (2), 109-28.
18. Fatemi, S. H.; Reutiman, T. J.; Folsom, T. D.; Bell, C.; Nos, L.; Fried, P.; Pearce, D. A.; Singh, S.; Siderovski, D. P.; Willard, F. S.; Fukuda, M. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 2006, 31 (9), 1888-99.
19. McCarthy, F. M.; Burgess, S. C.; van den Berg, B. H.; Koter, M. D.; Pharr, G. T. Differential detergent fractionation for non-electrophoretic eukaryote cell proteomics. J. Proteome Res. 2005, 4 (2), 316-24.
20. Cropley, J.; Gibson, V.; Rourke, C.; Hatcher, P.; Jones, D. N. C.; Reavill, C. Pharmacological profile of atypical antipsychotic drugs. J. Psychopharmacol. 2003, S17, A48.
21. Perez-Costas, E.; Guidetti, P.; Melendez-Ferro, M.; Kelley, J. J.; Roberts, R. C. Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J. Neural Transm. 2008, 115 (5), 745-53.
22. Olsen, C. K.; Brennum, L. T.; Kreilgaard, M. Using pharmacokinetic- pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur. J. Pharmacol. 2008, 584 (2-3), 318-27.
23. Swanson, L. W. Brain Maps: Structure of the Rat Brain, 2nd ed.; Elsevier: Amsterdam, 1998.
24. Uylings, H. B.; Groenewegen, H. J.; Kolb, B. Do rats have a prefrontal cortex. Behav. Brain Res. 2003, 146 (1-2), 3-17.
25. Levin, Y.; Schwarz, E.; Wang, L.; Leweke, F. M.; Bahn, S. Labelfree LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J. Sep. Sci. 2007, 30 (14), 2198-203.
26. Schwarz, E.; Levin, Y.; Wang, L.; Leweke, F. M.; Bahn, S. Peptide correlation: a means to identify high quality quantitative information in large-scale proteomic studies. J. Sep. Sci. 2007, 30 (14), 2190-7.
27. Levin, Y.; Wang, L.; Ingudomnukul, E.; Schwarz, E.; Baron-Cohen, S.; Palotas, A.; Bahn, S. Real-time evaluation of experimental variation in large-scale LC-MS/MS-based quantitative proteomics of complex samples. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2009, 877 (13), 1299-305.
28. Hughes, M. A.; Silva, J. C.; Geromanos, S. J.; Townsend, C. A. Quantitative proteomic analysis of drug-induced changes in mycobacteria. J. Proteome Res. 2006, 5 (1), 54-63.
29. Silva, J. C.; Denny, R.; Dorschel, C.; Gorenstein, M. V.; Li, G. Z.; Richardson, K.; Wall, D.; Geromanos, S. J. Simultaneous qualitative and quantitative analysis of the Escherichia coli proteome: a sweet tale. Mol. Cell. Proteomics 2006, 5 (4), 589-607.
30. Silva, J. C.; Denny, R.; Dorschel, C. A.; Gorenstein, M.; Kass, I. J.; Li, G. Z.; McKenna, T.; Nold, M. J.; Richardson, K.; Young, P.; Geromanos, S. Quantitative proteomic analysis by accurate mass retention time pairs. Anal. Chem. 2005, 77 (7), 2187-200.
31. Vissers, J. P.; Langridge, J. I.; Aerts, J. M. Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol. Cell. Proteomics 2007, 6 (5), 755-66.
32. Siripurapu, V.; Meth, J.; Kobayashi, N.; Hamaguchi, M. DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J. Mol. Biol. 2005, 346 (1), 83-9.
33. Salim, K.; Guest, P. C.; Skynner, H. A.; Bilsland, J. G.; Bonnert, T. P.; McAllister, G.; Munoz-Sanjuan, I. Identification of proteomic changes during differentiation of adult mouse subventricular zone progenitor cells. Stem Cells Dev. 2007, 16 (1), 143-65.
34. Tosato, S.; Dazzan, P.; Collier, D. Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr. Bull. 2005, 31 (3), 613-7.
35. Rushlow, W. J.; Seah, Y. H.; Belliveau, D. J.; Rajakumar, N. Changes in calcineurin expression induced in the rat brain by the administration of antipsychotics. J. Neurochem. 2005, 94 (3), 587-96.
36. Saviouk, V.; Moreau, M. P.; Tereshchenko, I. V.; Brzustowicz, L. M. Association of synapsin 2 with schizophrenia in families of Northern European ancestry. Schizophr. Res. 2007, 96 (1-3), 100-11.
37. Koh, H. Y.; Kim, D.; Lee, J.; Lee, S.; Shin, H. S. Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1. Genes Brain Behav. 2008, 7 (1), 120-8.
38. Anastasio, N. C.; Johnson, K. M. Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat. J. Neurochem. 2008, 104 (5), 1210-8.
39. Novak, G.; Seeman, P.; Tallerico, T. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. Synapse 2006, 59 (1), 61-8.
40. Lei, G.; Xia, Y.; Johnson, K. M. The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology 2008, 33 (6), 1343-53.
41. Bonelli, R. M.; Wenning, G. K. Pharmacological management of Huntington's disease: an evidence-based review. Curr. Pharm. Des. 2006, 12 (21), 2701-20.
42. Crespo-Facorro, B.; Perez-Iglesias, R.; Ramirez-Bonilla, M.; Martinez-Garcia, O.; Llorca, J.; Luis Vazquez-Barquero, J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J. Clin. Psychiatry 2006, 67 (10), 1511-21.
43. Gygi, S. P.; Rochon, Y.; Franza, B. R.; Aebersold, R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 1999, 19 (3), 1720-30.
44. Yamasue, H.; Iwanami, A.; Hirayasu, Y.; Yamada, H.; Abe, O.; Kuroki, N.; Fukuda, R.; Tsujii, K.; Aoki, S.; Ohtomo, K.; Kato, N.; Kasai, K. Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiatry Res. 2004, 131 (3), 195-207.
45. Lopez-Gil, X.; Babot, Z.; Amargos-Bosch, M.; Sunol, C.; Artigas, F.; Adell, A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32 (10), 2087-97.
46. Iwamoto, K.; Kato, T. Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist 2006, 12 (4), 349-61.
47. Piccoli, G.; Verpelli, C.; Tonna, N.; Romorini, S.; Alessio, M.; Nairn, A. C.; Bachi, A.; Sala, C. Proteomic analysis of activity-dependent synaptic plasticity in hippocampal neurons. J. Proteome Res. 2007, 6 (8), 3203-15.
48. Palfreyman, M. G.; Hook, D. J.; Klimczak, L. J.; Brockman, J. A.; Evans, D. M.; Altar, C. A. Novel directions in antipsychotic target identification using gene arrays. Curr. Drug Targets: CNS Neurol. Disord. 2002, 1 (2), 227-38.
49. Ogden, C. A.; Rich, M. E.; Schork, N. J.; Paulus, M. P.; Geyer, M. A.; Lohr, J. B.; Kuczenski, R.; Niculescu, A. B. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol. Psychiatry 2004, 9 (11), 1007-29.
50. Le-Niculescu, H.; McFarland, M. J.; Mamidipalli, S.; Ogden, C. A.; Kuczenski, R.; Kurian, S. M.; Salomon, D. R.; Tsuang, M. T.; Nurnberger, J. I.; Niculescu, A. B. Convergent Functional Genomics of bipolar disorder: from animal model pharmacogenomics to human genetics and biomarkers. Neurosci. Biobehav. Rev. 2007, 31 (6), 897-903.
51. Altar, C. A.; Vawter, M. P.; Ginsberg, S. D. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 2009, 34 (1), 18-54.
52. Prabakaran, S.; Swatton, J. E.; Ryan, M. M.; Huffaker, S. J.; Huang, J. T.; Griffin, J. L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K. S.; Karp, N. A.; Hester, S.; Tkachev, D.; Mimmack, M. L.; Yolken, R. H.; Webster, M. J.; Torrey, E. F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9 (7), 684-97, 643.
53. Tkachev, D.; Mimmack, M. L.; Ryan, M. M.; Wayland, M.; Freeman, T.; Jones, P. B.; Starkey, M.; Webster, M. J.; Yolken, R. H.; Bahn, S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362 (9386), 798-805.
54. MacDonald, M. L.; Eaton, M. E.; Dudman, J. T.; Konradi, C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol. Psychiatry 2005, 57 (9), 1041-51.
55. Behan, A. ; Byrne, C. ; Dunn, M. J. ; Cagney, G. ; Cotter, D. R., Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol. Psychiatry 2009, 14 (6), 601-613.
56. Karoutzou, G.; Emrich, H. M.; Dietrich, D. E. The myelinpathogenesis puzzle in schizophrenia: a literature review. Mol. Psychiatry 2008, 13 (3), 245-60.
57. Lane, H. Y.; Lee, C. C.; Liu, Y. C.; Chang, W. H. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 2005, 6 (2), 139-49.
58. Fatemi, S. H.; Folsom, T. D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35 (3), 528-48.
59. Rapoport, J. L.; Addington, A. M.; Frangou, S.; Psych, M. R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10 (5), 434-49.
60. Karlsgodt, K. H.; Sun, D.; Jimenez, A. M.; Lutkenhoff, E. S.; Willhite, R.; van Erp, T. G.; Cannon, T. D. Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia. Dev. Psychopathol. 2008, 20 (4), 1297-327.
61. Meisenzahl, E. M.; Koutsouleris, N.; Bottlender, R.; Scheuerecker, J.; Jager, M.; Teipel, S. J.; Holzinger, S.; Frodl, T.; Preuss, U.; Schmitt, G.; Burgermeister, B.; Reiser, M.; Born, C.; Moller, H. J. Structural brain alterations at different stages of schizophrenia: A voxel-based morphometric study. Schizophr. Res. 2008, 104 (1-3), 44-60.
62. Bai, O.; Chlan-Fourney, J.; Bowen, R.; Keegan, D.; Li, X. M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003, 71 (1), 127-31.
63. Chlan-Fourney, J.; Ashe, P.; Nylen, K.; Juorio, A. V.; Li, X. M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 2002, 954 (1), 11-20.
64. Ozaki, T. Comparative effects of dopamine D(1) and D(2) receptor antagonists on nerve growth factor protein induction. Eur. J. Pharmacol. 2000, 402 (1-2), 39-44.
65. Ozaki, T.; Mui, K.; Yamagami, S. Comparison of the effects of dopamine D1 and D2 receptor antagonists on nerve growth factor mRNA expression. Eur. J. Pharmacol. 1999, 369 (1), 133-43.
66. Linden, A. M.; Vaisanen, J.; Lakso, M.; Nawa, H.; Wong, G.; Castren, E. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J. Mol. Neurosci. 2000, 14 (1-2), 27-37.
67. Toro, C. T.; Deakin, J. F. Adult neurogenesis and schizophrenia: a window on abnormal early brain development. Schizophr. Res. 2007, 90 (1-3), 1-14.
68. Wakade, C. G.; Mahadik, S. P.; Waller, J. L.; Chiu, F. C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 2002, 69 (1), 72-9.
69. Dai, Y.; Wei, Z.; Sephton, C. F.; Zhang, D.; Anderson, D. H.; Mousseau, D. D. Haloperidol induces the nuclear translocation of phosphatidylinositol 3′-kinase to disrupt Akt phosphorylation in PC12 cells. J. Psychiatry Neurosci. 2007, 32 (5), 323-30.
70. Singh, R. K.; Shi, J.; Zemaitaitis, B. W.; Muma, N. A. Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J. Pharmacol. Exp. Ther. 2007, 322 (1), 133-40.
71. Jardemark, K. E.; Liang, X.; Arvanov, V.; Wang, R. Y. Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience 2000, 100 (1), 1-9.
72. Fatemi, S. H. Olanzapine increases glucogenesis by multiple pathways in brain and muscle. Mol. Psychiatry 2006, 11 (6), 524-5.
73. Engl, J.; Laimer, M.; Niederwanger, A.; Kranebitter, M.; Starzinger, M.; Pedrini, M. T.; Fleischhacker, W. W.; Patsch, J. R.; Ebenbichler, C. F. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol. Psychiatry 2005, 10 (12), 1089-96.
74. Girotti, F.; Carella, F.; Scigliano, G.; Grassi, M. P.; Soliveri, P.; Giovannini, P.; Parati, E.; Caraceni, T. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 1984, 47 (8), 848-52.